At the European Society of Cardiology congress in Paris the results of both the DAPA trial and the EU-CaRE RCT trial have been presented!
The longterm DAPA trial results were part of the late breaking trial session presented by DM Haanschoten, MD, Isala Zwolle. The EU-CaRE RCT results were presented by EP De Kluiver, MD PhD, Isala Zwolle.
According to the longterm results of the DAPA trial, prophylactic implantation of an implantable cardioverter defibrillator within 90 days in patients with STEMI undergoing PCI reduced the risk for death in certain high-risk patients.
The DAPA trial is a prospective, randomized study of patients at high risk for sudden death who had PCI to treat STEMI and were assigned ICD implantation plus conventional medical therapy or conventional medical therapy alone.
In total 266 patients were enrolled. During a median follow-up of 9 years, 24.4% of patients in the ICD group died compared with 35.6% of patients in the control group (P = 0.02). Sudden cardiac death was numerically lower in the ICD group (3.1% vs. 5.9%; P = 0.521).
- ESC TV: at ESC congress with Arif Elvan, MD PhD, Isala Zwolle
- Medscape Medical News: DAPA: Early ICD After Primary PCI-Treated STEMI Saves Lives
EU-CaRE RCT trial
The EU-CaRE RCT trial results demonstrated that a mobile CR (mCR) programme of 6 months for patients above 65 years of age who decline participation in conventional CR is superior in changing VO2peak at 6 and 12 months.
The EU-CaRE RCT is a multicenter (6 centers), multinational (5 countries), randomized controlled trial for an eHealth application in cardiac rehabilitation in Europe. READ MORE
In total 179 patients were enrolled. Relative VO2peak increased significantly over time in mCR (+1.6 mL kg-1 min-1 (95% CI 0.9 – 2.4) and +1.2 mL kg-1 min-1 (95% CI 0.4 – 2.0) for baseline to 6 months follow-up and baseline to 12 months follow-up respectively). Changes in relative VO2peak were different between groups at 6 and 12 months (p = 0.015 and p = 0.040 respectively).